Innovative approach aims to transform treatment for COPD and asthma.
A Breakthrough in Respiratory Care
AerWave Medical has successfully completed the first-in-human feasibility study of its ultrasound lung denervation therapy, a disease-modifying approach for chronic obstructive pulmonary disease (COPD) and asthma. The company also secured $12 million in funding to propel the advancement of this promising technology.
Simplified and Targeted Therapy
AerWave’s platform eliminates the complexity associated with traditional lung denervation by:
- Removing the need for fluoroscopic guidance, esophageal marker balloons, and multiple catheter exchanges.
- Delivering precise circumferential ablation in a single energy application.
- Avoiding sensitive areas, such as peri-esophageal nerves, ensuring safety.
The procedure’s single-shot approach allows for shorter, targeted treatments, with a universal catheter design that accommodates diverse airway anatomies.
Beyond Lung Denervation
AerWave’s ultrasound platform has the potential to address additional indications, including:
- Lung tumor ablation: Precise energy application for targeted tumor reduction.
- Lung volume reduction: Offering new solutions for chronic respiratory conditions.
A Scalable Solution
CEO Patrick Gallagher emphasized the significance of these milestones:
“Our technology addresses some of the most pressing challenges in respiratory care, offering a scalable, disease-modifying solution with the potential to improve patient outcomes.”
What’s Next
With its feasibility study complete and funding in place, AerWave is well-positioned to advance its platform, potentially redefining care for millions of patients worldwide.
Follow MEDWIRE.AI to stay updated on groundbreaking technologies inrespiratory care and other innovations transforming healthcare.
